Literature DB >> 18334992

Allogeneic transplantation for ALL in adults.

A Stein1, S J Forman.   

Abstract

Allogeneic transplantation is an effective treatment for adult patients with high-risk ALL, including patients in first or second remission. Although only a few studies have evaluated the optimal transplant regimens, the data would suggest that a TBI-based regimen results in better disease control. Although not as potent as it is in other hematologic malignancies, the GVL effect is an important component of achieving cure of ALL. Because of the toxicity of the fully ablative regimen, reduced-intensity transplants are being explored in older patients with ALL when the prognosis is especially poor with standard chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334992     DOI: 10.1038/bmt.2008.1

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

1.  Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.

Authors:  Anthony S Stein; Joycelynne M Palmer; Margaret R O'Donnell; Neil M Kogut; Ricardo T Spielberger; Marilyn L Slovak; Ni-Chun Tsai; David Senitzer; David S Snyder; Sandra H Thomas; Stephen J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2009-11       Impact factor: 5.742

2.  A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.

Authors:  Michael J Burke; Jatinder K Lamba; Stanley Pounds; Xueyuan Cao; Yogita Ghodke-Puranik; Bruce R Lindgren; Brenda J Weigel; Michael R Verneris; Jeffrey S Miller
Journal:  Am J Hematol       Date:  2014-06-27       Impact factor: 10.047

3.  Total body irradiation with step translation and dynamic field matching.

Authors:  Ho-Hsing Chen; Jay Wu; Keh-Shih Chuang; Jia-Fu Lin; Jia-Cheng Lee; Jin-Ching Lin
Journal:  Biomed Res Int       Date:  2013-07-01       Impact factor: 3.411

4.  Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia.

Authors:  Sabine Cerny-Reiterer; Renata A Meyer; Harald Herrmann; Barbara Peter; Karoline V Gleixner; Gabriele Stefanzl; Emir Hadzijusufovic; Winfried F Pickl; Wolfgang R Sperr; Junia V Melo; Hiroshi Maeda; Ulrich Jäger; Peter Valent
Journal:  Oncotarget       Date:  2014-03-15

5.  Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.

Authors:  Nicola Gökbuget; Hervé Dombret; Sebastian Giebel; Monika Brüggemann; Michael Doubek; Robin Foa; Dieter Hoelzer; Christopher Kim; Giovanni Martinelli; Elena Parovichnikova; Josep Maria Ribera; Marieke Schoonen; Catherine Tuglus; Gerhard Zugmaier; Renato Bassan
Journal:  Eur J Haematol       Date:  2020-01-24       Impact factor: 2.997

Review 6.  Indications for Allogeneic HCT in Adults with Acute Lymphoblastic Leukemia in First Complete Remission.

Authors:  Shukaib Arslan; Vinod Pullarkat; Ibrahim Aldoss
Journal:  Curr Treat Options Oncol       Date:  2021-06-07

7.  The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells.

Authors:  Gabriele Stefanzl; Daniela Berger; Sabine Cerny-Reiterer; Katharina Blatt; Gregor Eisenwort; Wolfgang R Sperr; Gregor Hoermann; Karin Lind; Alexander W Hauswirth; Peter Bettelheim; Heinz Sill; Junia V Melo; Ulrich Jäger; Peter Valent
Journal:  Oncotarget       Date:  2017-06-28

8.  Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.

Authors:  Katharina Blatt; Ingeborg Menzl; Gregor Eisenwort; Sabine Cerny-Reiterer; Harald Herrmann; Susanne Herndlhofer; Gabriele Stefanzl; Irina Sadovnik; Daniela Berger; Alexandra Keller; Alexander Hauswirth; Gregor Hoermann; Michael Willmann; Thomas Rülicke; Heinz Sill; Wolfgang R Sperr; Christine Mannhalter; Junia V Melo; Ulrich Jäger; Veronika Sexl; Peter Valent
Journal:  Neoplasia       Date:  2018-05-15       Impact factor: 5.715

9.  In Situ Leukemia as Manifestation of Relapse After Allogeneic Transplantation of Bone Marrow of ALL B: A Case Report.

Authors:  Irline Cordeiro de Macedo Pontes; Marjory Medeiro Passos Teixeira; Naisa Bezerra de Carvalho; Milton da Silva Linhares Junior; Luis Fabio Barbosa Botelho
Journal:  J Hematol (Brossard)       Date:  2018-09-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.